Jaguar Health (JAGX) EBITDA Margin (2015 - 2026)
Jaguar Health (JAGX) reported EBITDA Margin of 50.23% for Q1 2026, up 47575.0% year-over-year from N/an in Q1 2025, and up 107.65% quarter-over-quarter from 656.63% in Q4 2025.
Jaguar Health (JAGX) EBITDA Margin (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 12 years of EBITDA Margin data on file, last reported at 50.23% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 50.23%, up 47575.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 88.96% (up 18837.0% YoY), and the FY2025 annual result was 398.82%, down 13506.0% from the prior year.
- EBITDA Margin advanced to 50.23% in Q1 2026 per JAGX's latest filing, from 656.63% in the prior quarter.
- Over five years, EBITDA Margin peaked at 50.23% in Q1 2026 and troughed at 58770.0% in Q1 2022.
- A 5-year average of 6140.39% and a median of 312.37% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin sank 5806363 bps in 2022, then surged 3689222 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 19643.75% in 2022, then surged by 98 bps to 328.57% in 2023, then advanced by 29 bps to 232.46% in 2024, then sank by 182 bps to 656.63% in 2025, then jumped by 108 bps to 50.23% in 2026.
- Business Quant data shows JAGX's EBITDA Margin at 50.23% in Q1 2026, 656.63% in Q4 2025, and 234.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | 50.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.23% |
| Dec 31, 2025 | -656.63% |
| Sep 30, 2025 | -234.77% |
| Jun 30, 2025 | -268.78% |
| Mar 31, 2025 | -425.52% |
| Dec 31, 2024 | -232.46% |
| Sep 30, 2024 | -233.66% |
| Jun 30, 2024 | -264.50% |
| Mar 31, 2024 | -349.43% |
| Dec 31, 2023 | -328.57% |
| Sep 30, 2023 | -312.37% |
| Jun 30, 2023 | -302.77% |
| Mar 31, 2023 | -21,877.78% |
| Dec 31, 2022 | -19,643.75% |
| Sep 30, 2022 | -314.16% |
| Jun 30, 2022 | -221.81% |
| Mar 31, 2022 | -58,770.00% |
| Dec 31, 2021 | -506.89% |
| Sep 30, 2021 | -1,512.54% |
| Jun 30, 2021 | -3,055.41% |